Health Discovery Corporation (OTCBB: HDVY) announced today that
on December 18, 2012, the Board of Directors appointed Dr. John
Norris as its new CEO. He succeeds Dr. Stephen Barnhill, who
founded HDC, served as Chairman and CEO for 9 years and brought the
Company to profitability in Q3 2012.
Dr. Norris, 65, until his appointment as CEO, was Executive Vice
President, Chief Technology Officer, and Chief Regulatory Officer
of Health Discovery Corporation and had served in that capacity for
the past three years.
“I look forward to assuming the role of CEO at Health Discovery
Corporation and leading the Company to its next level of success,”
stated John A. Norris, JD, MBA, Chief Executive Officer of Health
Discovery Corporation, “and I want to personally thank Dr. Stephen
Barnhill for his many years of dedication to and leadership of HDC
as Chairman and CEO from its inception through its profitability. I
also want to acknowledge his contribution as an inventor of some 40
of HDC’s patents which are valuable assets of the Company. I look
forward to receiving his guidance and advice as I transition into
my role as CEO.”
Dr. Norris is a Former Principal Deputy Commissioner
(second-in-command) and Chief Operating Officer (COO) of the US FDA
(Food and Drug Administration), where with Former FDA Commissioner,
Dr. Frank Young, he co-led the last major reform of the FDA. This
work was performed under the overall leadership of President Ronald
Reagan, HHS Secretaries Margaret Heckler and Dr. Otis Bowen, FDA
Commissioner Dr. Frank Young, Senator Orrin Hatch, and Congressman
Paul Rogers.
Dr. Norris is a Former Director and Co-Leader of the turnaround
of Summit Technology (NASDAQ: BEAM), inventor of computer-driven
(semi-automated) laser eye surgery. The FDA approved Summit’s
version of LASIK using the Summit Apex Plus Excimer Laser
Workstation. Alcon Laboratories Inc. (NYSE: ACL), the eye-products
unit of Nestle, S.A., acquired Summit Technology, Inc., for $893
million. Summit Technology, based in Waltham, Massachusetts, had
sales of $111 million.
In addition, Dr. Norris is a Former Corporate Officer, Corporate
Executive Vice President, and Worldwide Managing Director for Life
Sciences Coaching and Consulting at Hill & Knowlton. With 83
offices in 46 countries, Hill and Knowlton is one of the world's
largest marketing and management coaching and consulting firms. It
represents many of the world's premier healthcare, life sciences,
and healthcare-IT companies
Dr. Norris is a Director of Ischemix, a developer of next
generation heart medicines for advancing ischemia-reperfusion
therapy. In addition, he was CEO and is now Chairman of Needlebot,
a developer and manufacturer of a next generation software search
engine for searching and analyzing “unstructured text” contained in
many sources, including nurses' notes, doctors' notes, medical
records, medical literature, and clinical trial records, at both
the Internet and Enterprise levels, as well as CEO and now Chairman
of Norris Capital, a corporate finance and holding company and a
boutique legal, regulatory, financial, marketing, and
management/strategy coaching and consulting firm. He is also a
Director of Last Call Ventures, LLC, a food-supplement company.
Dr. Norris was CEO and is now Chairman of FDDH (Food, Drug,
Device, and Healthcare), a healthcare-delivery and healthcare-IT
coaching firm, and was CEO and is now Chairman of the Joseph D.
Norris, Esq., Health Law and Public Policy Fund. The Joseph D.
Norris, Esq., Health Law and Public Policy Fund supports university
scholarships for health law and public policy student training.
Dr. Norris is also the Founder and Former
Faculty-Editor-in-Chief and CEO of the academic journal, The
American Journal of Law and Medicine, which he founded at Harvard,
MIT, and Boston University, and which is now housed at Boston
University.
Dr. Norris is the Former Chairman of Global MedChoices, which is
developing a planned response to US healthcare reform at the
convergence of three elements: (1) advanced healthcare-IT, (2)
specialty surgical services, and (3) key medical tourism
locations.
He is also a Former Chairman of the American Society of Law,
Medicine, and Ethics, a Former Vice-Chairman of the Massachusetts
4-H Foundation, and a Former Vice-Chairman of the American Bar
Association’s (ABA) Health Law Committee.
Dr. Norris has been a consultant to the senior management of
global companies, including: Pfizer, Merck, J&J, and Glaxo.
Dr. Norris received a BA in Economics, with minors in Political
Science and Chemical Engineering, from the University of Rochester
(where he was a two varsity-sport athlete, and became a member of
the university’s Trustee’s Council); a JD with emphasis in health
law, corporate law, and international law from Cornell University’s
Law School, where he was Editor-in-Chief of The International Law
Journal; an MBA with emphasis in healthcare and healthcare-IT
policy and management, from Cornell University’s S.C. Johnson
Graduate School of Management; and a Graduate Certificate from
Harvard University’s Kennedy School of Government. He is also a
Former Harvard faculty member, where he taught health policy and
management, including healthcare-IT reform,
healthcare-delivery-system reform, and FDA reform.
According to HDC Board Chairman, Dr. Joe McKenzie, “John has
served with distinction for the past three years, and we intend to
rely on his global vision of the future of
healthcare-delivery-system reform, of healthcare-IT reform, and of
FDA reform to drive the transformation of HDC into its next phase
of growth.”
HDC Director, Dr. Herb Fritsche stated, “I have known John for a
long time and have worked closely with him over the past three
years. I can attest to his impeccable personal integrity,
intellectual honesty, outstanding vision, and keen knowledge,
insights, and judgment regarding the future of advanced healthcare
technology, healthcare-delivery-system reform, healthcare-IT
reform, and FDA reform. His strong business reputation, and his
exceptional advisory and executive capabilities, are all well known
to me.”
HDC Director, Mr. Sumio Takeichi commented, “I have worked
closely with John for nearly 20 years, both on boards and in
business ventures, and I, too, can attest to his honesty,
integrity, courage, insight, and intelligence when under pressure.
He has the best values, capabilities, and experiences of anyone I
know, for teasing potential out of HDC’s technologies and turning
the Company’s fortunes in a strongly positive direction. His
availability and his willingness to take on that challenge are both
God sends.”
Dr. Stephen Barnhill, outgoing CEO, stated, “I have worked
closely with John off and on over the past 20 years and I admire
John for his keen vision, his prior successes, his comprehensive
understanding of HDC’s technology and his business insights and
contacts. He is the perfect choice to succeed me, and I am
absolutely committed to assisting him with a smooth transition and
supporting him in any way that I can to bring success to HDC and
its shareholders.”
About Health Discovery Corporation
Health Discovery Corporation is a molecular diagnostics company
that uses advanced mathematical techniques to analyze large amounts
of data to uncover patterns that might otherwise be undetectable.
It operates primarily in the emerging field of personalized
medicine where such tools are critical to scientific discovery. Its
primary business consists of licensing its intellectual property
and developing its own product line of biomarker-based diagnostic
tests that include human genes and genetic variations, as well as
gene, protein, and metabolic expression differences and image
analysis in digital pathology and radiology. For more information,
see www.healthdiscoverycorp.com.
Forward-Looking Statements
This document contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995,
the accuracy of which is necessarily subject to risks and
uncertainties, including, without limitation, statements regarding
future performance, opportunities and investments, and anticipated
results in general. From time to time the Company may make other
forward-looking statements relating to other matters, including
without limitation, commercialization plans and strategic
partnerships. Actual results may differ materially due to a variety
of factors, including, among other things, the acceptance of our
approach to applying mathematics computer science and physics into
the disciplines of biology, organic chemistry and medicine and our
products and technologies associated with those approaches, the
ability to develop or commercialize new drugs, therapies or other
products based on our approaches, and other factors set forth from
time to time in the Company’s Securities and Exchange Commission
filings.
All forward-looking statements and cautionary statements
included in this document are made as of the date hereof based on
information available to the Company as of the date hereof, and the
Company assumes no obligation to update any forward-looking
statement or cautionary statement.
Health Discovery (CE) (USOTC:HDVY)
Gráfica de Acción Histórica
De Oct 2024 a Nov 2024
Health Discovery (CE) (USOTC:HDVY)
Gráfica de Acción Histórica
De Nov 2023 a Nov 2024
